Several prospective clinical studies are investigating strategies to mitigate acute rejection in kidney transplant recipients treated with ICI: continuing tacrolimus (NCT03816332), conversion to mammalian target of rapamycin (NCT04339062), or maintaining the baseline immunosuppression regimen24,25. This evidence concerns the gene MTOR and medical procedure.